Broadcasting from EULAR 2024: TNX-102 SL Significantly Reduces Daily Pain, Improves Fibromyalgia Symptoms
Phase 3 data showed TNX-102 SL (sublingual cyclobenzaprine HCI; Tonmya) significantly reduced daily pain and improved broad fibromyalgia symptoms.
Tonix Pharmaceuticals presented a poster of their pivotal trial, RESILIENT, at the Annual European Congress of Rheumatology (EULAR) 2024 in Vienna, Austria. The study evaluated TNX-102 SL on pain and broad fibromyalgia symptom management.
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
